BiotechTube

AMPHORA

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Jul 24, 2017 → Nov 29, 2018

NCT ID
NCT03243305

About AMPHORA

AMPHORA is a phase 3 stage product being developed by Evofem Biosciences for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT03243305. Target conditions include Contraception.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03243305Phase 3Completed

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
41
Relugolix Combination TherapySumitomo PharmaPhase 3
77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEJohnson & JohnsonPhase 1
33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
23
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
oral ulipristal acetateMerckPhase 1
33
Etonogestrel contraceptive implantMerckApproved
85
Rifampin 600 MGMerckApproved
85
Long Acting Reversible Contraception (LARC)MerckApproved
85
Etonogestrel contraceptive implantMerckApproved
85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
22
Sayana PressPfizerApproved
84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
76

Other Products from Evofem Biosciences

LIPO-202 + PlaceboPhase 3
69
LIPO-202 + PlaceboPhase 3
69
Conceptrol + AmphoraPhase 3
69
EVO100 + PlaceboPhase 3
69
EVO100 + PlaceboPhase 2/3
57